Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Fallet

Showing results (11-20 of 51) with videos related to

Pageof 6
Sort By:
European Respiratory Review : an Official Journal of the European Respiratory Society|October 21, 2021
Lung cancer is also a hereditary diseasePatrick R Benusiglio, Vincent Fallet, Mateo Sanchis-Borja, et al.
Bulletin Du Cancer|November 21, 2015
[Nivolumab, a new hope in non-small cell lung cancer]Ronan Flippot, Vincent Fallet, Benjamin Besse, et al.
Translational Lung Cancer Research|August 25, 2021
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies-a narrative reviewVincent Fallet, Lise Matton, Antoine Schernberg, et al.
Annales De Pathologie|January 19, 2016
[Pulmonary sarcomatoid carcinoma]Martine Antoine, Thibault Vieira, Vincent Fallet, et al.
Presse Medicale (Paris, France : 1983)|November 25, 2025
Pulmonary toxicity of immune-checkpoint inhibitorsCédric Mahiat, Jacques Cadranel, Vincent Fallet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2019
Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung CancerMateo Sanchis-Borja, Antoine Parrot, Déborah Sroussi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2019
Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to BrigatinibCamille Mehlman, Nouha Chaabane, Roger Lacave, et al.
Bulletin Du Cancer|December 23, 2017
[Lung cancer in HIV-infected patients]Charlotte Domblides, Anthony Canellas, Marie Wislez, et al.
Clinical Lung Cancer|September 20, 2022
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case ReportPascal Wang, Lise Matton, Fatima Kebir, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?Sébastien Gendarme, Lise Matton, Martine Antoine, et al.
Pageof 6

Showing results (11-20 of 51) with videos related to

Sort By:
Pageof 6
European Respiratory Review : an Official Journal of the European Respiratory Society|October 21, 2021
Lung cancer is also a hereditary diseasePatrick R Benusiglio, Vincent Fallet, Mateo Sanchis-Borja, et al.
Bulletin Du Cancer|November 21, 2015
[Nivolumab, a new hope in non-small cell lung cancer]Ronan Flippot, Vincent Fallet, Benjamin Besse, et al.
Translational Lung Cancer Research|August 25, 2021
Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies-a narrative reviewVincent Fallet, Lise Matton, Antoine Schernberg, et al.
Annales De Pathologie|January 19, 2016
[Pulmonary sarcomatoid carcinoma]Martine Antoine, Thibault Vieira, Vincent Fallet, et al.
Presse Medicale (Paris, France : 1983)|November 25, 2025
Pulmonary toxicity of immune-checkpoint inhibitorsCédric Mahiat, Jacques Cadranel, Vincent Fallet, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 28, 2019
Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung CancerMateo Sanchis-Borja, Antoine Parrot, Déborah Sroussi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2019
Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to BrigatinibCamille Mehlman, Nouha Chaabane, Roger Lacave, et al.
Bulletin Du Cancer|December 23, 2017
[Lung cancer in HIV-infected patients]Charlotte Domblides, Anthony Canellas, Marie Wislez, et al.
Clinical Lung Cancer|September 20, 2022
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case ReportPascal Wang, Lise Matton, Fatima Kebir, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?Sébastien Gendarme, Lise Matton, Martine Antoine, et al.
Pageof 6